IP Library Granted Patent US 10,017,810
Granted Patent B2
US 10,017,810 · App. 15/269,448 · Granted Jul 10, 2018

Methods for determining a nucleotide sequence contiguous to a known target nucleotide sequence

Inventors: Anthony John Iafrate (Newton, MA); Long Phi Le (Boston, MA); Zongli Zheng (Boston, MA)
Assignee: THE GENERAL HOSPITAL CORPORATION
C12Q1/6855C12Q1/6806C12Q1/6874
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,017,810
App. No.
15/269,448
Granted
Jul 10, 2018
Kind
B2
Abstract

The technology described herein is directed to methods of determining oligonucleotide sequences, e.g. by enriching target sequences prior to sequencing the sequences.

Claims (26)

1. A method for preparing a nucleic acid for sequencing, the method comprising:

(i) ligating a universal oligonucleotide tail adaptor that comprises a first ligatable duplex end and a second unpaired end to a nucleic acid comprising a known target nucleotide sequence to produce a ligation product, the universal oligonucleotide tail adaptor comprising an amplification strand and a blocking strand, wherein a 3′ duplex portion of the amplification strand and a 5′ duplex portion of the blocking strand are substantially complementary and form the first ligatable duplex end;

(ii) amplifying the ligation product using a first target-specific primer that specifically anneals to the known target nucleotide sequence and a first adaptor primer having a nucleotide sequence identical to a first portion of the amplification strand; and

(iii) amplifying an amplification product of (ii) using a second target-specific primer that specifically anneals to the amplification product of (ii) and a second adaptor primer having a nucleotide sequence identical to a second portion of the amplification strand, wherein the second target-specific primer is nested relative to the first target-specific primer.

2. The method of claim 1 , wherein the entirety of the blocking strand is a duplex portion that is substantially complementary to the 3′ duplex portion of the amplification strand.

3. The method of claim 1 , wherein the blocking strand further comprises a 3′ unpaired portion which is not substantially complementary to the 5′ unpaired portion of the amplification strand.

4. The method of claim 1 , wherein the duplex portions of the amplification and blocking strands are at least 95% complementary, at least 98% complementary, at least 99% complementary, or 100% complementary.

5. The method of claim 1 , wherein the nucleic acid is a deoxyribonucleic acid.

6. The method of claim 5 , wherein the method further comprises subjecting a ribonucleic acid to a reverse transcriptase regimen to generate the deoxyribonucleic acid.

7. The method of claim 1 further comprising, prior to step (i), mechanically shearing a nucleic acid preparation to produce the nucleic acid comprising the known target nucleotide sequence.

8. The method of claim 7 further comprising, prior to step (i), end-repairing the nucleic acid to blunt the ends of the nucleic acid produced by mechanically shearing the nucleic acid preparation.

9. The method of claim 7 further comprising, prior to step (i), phosphorylating the nucleic acid.

10. The method of claim 1 further comprising, prior to step (i), adenylating the nucleic acid to produce a 3′-adenosine overhang on the nucleic acid.

11. The method of claim 1 , wherein ligating in step (i) comprises performing an overhang ligation reaction.

12. The method of claim 1 , wherein ligating in step (i) comprises performing a TA ligation reaction.

13. The method of claim 1 , wherein the first target-specific primer can specifically anneal to the known target nucleotide sequence at an annealing temperature in a range of 61° C. to 72° C.

14. The method of claim 1 , wherein the known target nucleotide sequence comprises a sequence associated with a gene rearrangement.

15. The method of claim 1 , wherein the universal oligonucleotide tail adaptor further comprises a barcode portion.

16. A method for preparing a nucleic acid for sequencing, the method comprising:

(i) ligating a universal oligonucleotide tail adaptor that comprises a first ligatable duplex end and a second unpaired end to a nucleic acid comprising a known target nucleotide sequence to produce a ligation product, the universal oligonucleotide tail adaptor comprising an amplification strand and a blocking strand, wherein a 3′ duplex portion of the amplification strand and a 5′ duplex portion of the blocking strand are substantially complementary and form the first ligatable duplex end;

(ii) amplifying the ligation product using a first target-specific primer that specifically anneals to the known target nucleotide sequence and a first adaptor primer having a nucleotide sequence identical to a first portion of the amplification strand; and

(iii) amplifying an amplification product of (ii) using a second target-specific primer that specifically anneals to the amplification product of (ii) and a second adaptor primer having a nucleotide sequence identical to a second portion of the amplification strand, wherein ligating in step (i) comprises performing an overhang ligation reaction, and wherein the universal oligonucleotide tail adaptor further comprises a barcode portion.

17. The method of claim 16 further comprising, prior to step (i), phosphorylating the nucleic acid.

18. The method of claim 16 further comprising, prior to step (i), adenylating the nucleic acid to produce a 3′-adenosine overhang on the nucleic acid.

19. The method of claim 16 , wherein ligating in step (i) comprises performing a TA ligation reaction.

20. The method of claim 16 further comprising sequencing an amplification product of (iii) using a first sequencing primer and a second sequencing primer.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2021
From: PERCEPTIVE CREDIT HOLDINGS III, LP
To: ARCHERDX, LLC
Reel/Frame 056069/0305 →
PATENT SECURITY AGREEMENT Recorded Oct 6, 2020
From: ARCHERDX, LLC
To: PERCEPTIVE CREDIT HOLDINGS III, LP
Reel/Frame 053992/0919 →
RELEASE OF SECURITY INTEREST Recorded Oct 2, 2020
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: ARCHERDX, INC.
Reel/Frame 053960/0565 →
MERGER AND CHANGE OF NAME Recorded Oct 2, 2020
From: ARCHERDX, INC.; APOLLO MERGER SUB B LLC
To: ARCHERDX, LLC
Reel/Frame 053965/0492 →
PATENT SECURITY AGREEMENT Recorded May 10, 2019
From: ARCHERDX
To: PERCEPTIVE CREDIT HOLDINGS II, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 049149/0696 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2016
From: IAFRATE, ANTHONY JOHN; LE, LONG PHI; ZHENG, ZONGLI
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 039889/0348 →
Continuity (4)
Continuation 13793564 · Mar 11, 2013
Provisional Application 61645364 · May 10, 2012
Provisional Application 61679302 · Aug 3, 2012
Related Publication 20170226575A1 · Aug 10, 2017
Cited By (31)
US 12,203,142 US 12,221,653 US 12,234,509 US 12,260,934 US 12,270,073 US 12,305,229 US 12,305,235 US 12,371,732 US 12,371,746 US 12,385,096 US 12,410,476 US 12,460,264 US 12,486,542 US 12,492,429 US 12,509,728 US 12,512,183 US 12,516,385 US 12,553,083 US 12,553,086 US 12,571,034 US 12,571,039 US 12,571,043 US 12,571,047 US 12,624,394 US 12,630,864 US 12,644,149 US 12,649,946 US 12,655,483 US 12,662,704 US 12,706,180 US 12,716,090